Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
71
BEAM Quote, Financials, Valuation and Earnings
Last price:
$28.15
Seasonality move
:
-3.39%
Day range:
$27.50 - $28.29
52-week range:
$13.53 - $35.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
47.43x
P/B ratio:
2.96x
Volume:
866.1K
Avg. volume:
1.9M
1-year change:
-2.33%
Market cap:
$2.9B
Revenue:
$63.5M
EPS (TTM):
-$4.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BEAM
Beam Therapeutics, Inc.
|
$12.7M | -$1.01 | -54.98% | -2.35% | $45.93 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
NTLA
Intellia Therapeutics, Inc.
|
$14.1M | -$1.00 | -5.94% | -24.06% | $22.43 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $788.28 |
|
RGEN
Repligen Corp.
|
$181.7M | $0.41 | 15.06% | 289.59% | $189.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BEAM
Beam Therapeutics, Inc.
|
$28.15 | $45.93 | $2.9B | -- | $0.00 | 0% | 47.43x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.11 | $109.25 | $1.8B | 50.36x | $0.00 | 0% | 2.01x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.59 | $22.43 | $1.1B | -- | $0.00 | 0% | 17.47x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$783.71 | $788.28 | $82.4B | 18.76x | $0.88 | 0.45% | 6.06x |
|
RGEN
Repligen Corp.
|
$165.66 | $189.22 | $9.3B | 6,420.93x | $0.00 | 0% | 13.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 2.089 | 6.16% | 5.89x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.323 | 4.9% | 5.57x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
RGEN
Repligen Corp.
|
24.85% | 1.126 | 9.16% | 6.86x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
RGEN
Repligen Corp.
|
$90.6M | $14.8M | 0.06% | 0.09% | 7.83% | $42.7M |
Beam Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns BEAM or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of 10.59%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About BEAM or ANIP?
Beam Therapeutics, Inc. has a consensus price target of $45.93, signalling upside risk potential of 65.39%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.33%. Given that Beam Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BEAMBeam Therapeutics, Inc.13 2 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is BEAM or ANIP More Risky?
Beam Therapeutics, Inc. has a beta of 2.213, which suggesting that the stock is 121.346% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock BEAM or ANIP?
Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BEAM or ANIP?
Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 47.43x versus 2.01x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M
-
Which has Higher Returns BEAM or FOLD?
Amicus Therapeutics, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of 10.24%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About BEAM or FOLD?
Beam Therapeutics, Inc. has a consensus price target of $45.93, signalling upside risk potential of 65.39%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that Beam Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BEAMBeam Therapeutics, Inc.13 2 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is BEAM or FOLD More Risky?
Beam Therapeutics, Inc. has a beta of 2.213, which suggesting that the stock is 121.346% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock BEAM or FOLD?
Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BEAM or FOLD?
Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 47.43x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns BEAM or NTLA?
Intellia Therapeutics, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -735.19%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About BEAM or NTLA?
Beam Therapeutics, Inc. has a consensus price target of $45.93, signalling upside risk potential of 65.39%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 133.91%. Given that Intellia Therapeutics, Inc. has higher upside potential than Beam Therapeutics, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Beam Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BEAMBeam Therapeutics, Inc.13 2 0 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is BEAM or NTLA More Risky?
Beam Therapeutics, Inc. has a beta of 2.213, which suggesting that the stock is 121.346% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.
-
Which is a Better Dividend Stock BEAM or NTLA?
Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BEAM or NTLA?
Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 47.43x versus 17.47x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M NTLAIntellia Therapeutics, Inc.17.47x -- $13.8M -$101.3M
-
Which has Higher Returns BEAM or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of 38.89%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About BEAM or REGN?
Beam Therapeutics, Inc. has a consensus price target of $45.93, signalling upside risk potential of 65.39%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that Beam Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BEAMBeam Therapeutics, Inc.13 2 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is BEAM or REGN More Risky?
Beam Therapeutics, Inc. has a beta of 2.213, which suggesting that the stock is 121.346% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock BEAM or REGN?
Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BEAM or REGN?
Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 47.43x versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M REGNRegeneron Pharmaceuticals, Inc.6.06x 18.76x $3.8B $1.5B
-
Which has Higher Returns BEAM or RGEN?
Repligen Corp. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of 7.9%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Repligen Corp.'s return on equity of 0.09%.
Company Gross Margin Earnings Per Share Invested Capital BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B RGENRepligen Corp.47.99% $0.26 $2.8B -
What do Analysts Say About BEAM or RGEN?
Beam Therapeutics, Inc. has a consensus price target of $45.93, signalling upside risk potential of 65.39%. On the other hand Repligen Corp. has an analysts' consensus of $189.22 which suggests that it could grow by 14.22%. Given that Beam Therapeutics, Inc. has higher upside potential than Repligen Corp., analysts believe Beam Therapeutics, Inc. is more attractive than Repligen Corp..
Company Buy Ratings Hold Ratings Sell Ratings BEAMBeam Therapeutics, Inc.13 2 0 RGENRepligen Corp.14 5 0 -
Is BEAM or RGEN More Risky?
Beam Therapeutics, Inc. has a beta of 2.213, which suggesting that the stock is 121.346% more volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.110, suggesting its more volatile than the S&P 500 by 11.028%.
-
Which is a Better Dividend Stock BEAM or RGEN?
Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BEAM or RGEN?
Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Repligen Corp. quarterly revenues of $188.8M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Repligen Corp.'s net income of $14.9M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Repligen Corp.'s PE ratio is 6,420.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 47.43x versus 13.20x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M RGENRepligen Corp.13.20x 6,420.93x $188.8M $14.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
